Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04276415 | GIST
Previous Study | Return to List | Next Study

DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04276415
Recruitment Status : Recruiting
First Posted : February 19, 2020
Last Update Posted : May 11, 2020
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

Brief Summary:
This study will assess the safety, efficacy, and pharmacokinetics of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST).

Condition or disease Intervention/treatment Phase
Gastrointestinal Stromal Tumors Drug: DS-6157a Phase 1

Detailed Description:

This study is a two-part, multicenter, open-label, multiple-dose, first-in-human study of the antibody-drug conjugate (ADC) DS-6157a given as a single agent to participants with gastrointestinal stromal tumor (GIST).

This study will include 2 parts:

  1. Dose Escalation (Part 1)
  2. Dose Expansion (Part 2)

Dose Escalation: Participants with histopathologically documented advanced GIST not amenable to curative therapy may be included in which the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of DS-6157a monotherapy will be determined.

Dose Expansion: Once the RDE(s) is established for DS-6157a (Part 1), enrollment in Dose Expansion (Part 2) will commence in 2 cohorts. Participants with GIST who have progressed on or are intolerant to imatinib (IM) and at least one post-IM treatment will be enrolled in Cohort 1, and participants with GIST who progressed on IM or who are intolerant to IM (2nd line) will be enrolled in Cohort 2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Subjects With Advanced Gastrointestinal Stromal Tumor
Actual Study Start Date : May 7, 2020
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : October 2024


Arm Intervention/treatment
Experimental: Dose Escalation: 1.6 mg/kg
Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous infusion of DS-6157a 1.6 mg/kg.
Drug: DS-6157a
Administered as a single agent intravenously (IV) every 3 weeks

Experimental: Dose Escalation: 3.2 mg/kg
Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous infusion of DS-6157a 3.2 mg/kg.
Drug: DS-6157a
Administered as a single agent intravenously (IV) every 3 weeks

Experimental: Dose Escalation: 4.8 mg/kg
Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous infusion of DS-6157a 4.8 mg/kg.
Drug: DS-6157a
Administered as a single agent intravenously (IV) every 3 weeks

Experimental: Dose Escalation: 6.4 mg/kg
Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous infusion of DS-6157a 6.4 mg/kg.
Drug: DS-6157a
Administered as a single agent intravenously (IV) every 3 weeks

Experimental: Dose Escalation: 8.0 mg/kg
Participants with advanced gastrointestinal stromal tumor (GIST) who received an intravenous infusion of DS-6157a 8.0 mg/kg.
Drug: DS-6157a
Administered as a single agent intravenously (IV) every 3 weeks

Experimental: Dose Expansion: Cohort 1 (3rd line or later) treated at RDE
Participants who have been previously treated with imatinib and at least one post-imatinib treatment will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
Drug: DS-6157a
Administered as a single agent intravenously (IV) every 3 weeks

Experimental: Dose Expansion: Cohort 2 (2nd line) treated at RDE
Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on or are intolerant to imatinib (IM) (2nd line) will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
Drug: DS-6157a
Administered as a single agent intravenously (IV) every 3 weeks




Primary Outcome Measures :
  1. Number of participants with dose-limiting toxicities (DLT) following intravenous administration of DS-6157a in patients with advanced gastrointestinal stromal tumors (GIST) [ Time Frame: Baseline up to 5 years post-treatment ]
  2. Summary of most frequently reported (≥10%) treatment-emergent adverse events (TEAEs) following intravenous administration of DS-6157a in patients with advanced gastrointestinal stromal tumors (GIST) [ Time Frame: Baseline up to 5 years post-treatment ]
  3. Objective response rate (ORR) following intravenous administration of DS-6157a in patients with advanced gastrointestinal stromal tumors (GIST) (Dose expansion) [ Time Frame: Baseline up to 5 years post-treatment ]
  4. Duration of response (DoR) following intravenous administration of DS-6157a in patients with advanced gastrointestinal stromal tumors (GIST) (Dose expansion) [ Time Frame: Baseline up to 5 years post-treatment ]
  5. Disease control rate (DCR) following intravenous administration of DS-6157a in patients with advanced gastrointestinal stromal tumors (GIST) (Dose expansion) [ Time Frame: Baseline up to 5 years post-treatment ]
  6. Progression-free survival (PFS) following intravenous administration of DS-6157a in patients with advanced gastrointestinal stromal tumors (GIST) (Dose expansion) [ Time Frame: Baseline up to 5 years post-treatment ]

Secondary Outcome Measures :
  1. Pharmacokinetic Analysis: Area under the plasma concentration-time curve up to the last quantifiable time (AUClast) for DS-6157a, total anti-GPR20 antibody, and MAAA-1181a following intravenous administration of DS-6157a [ Time Frame: Post Cycle 1 and Cycle 3 doses (each cycle is 21 days) ]
  2. Pharmacokinetic Analysis: Area under the plasma concentration-time curve in the dosing interval (AUCtau) for DS-6157a, total anti-GPR20 antibody, and MAAA-1181a following intravenous administration of DS-6157a [ Time Frame: Post Cycle 1 and Cycle 3 doses (each cycle is 21 days) ]
  3. Pharmacokinetic Analysis: Time to maximum plasma concentration (Tmax) for DS-6157a, total anti-GPR20 antibody, and MAAA-1181a following intravenous administration of DS-6157a [ Time Frame: Post Cycle 1 and Cycle 3 doses (each cycle is 21 days) ]
  4. Pharmacokinetic Analysis: Maximum plasma concentration (Cmax) for DS-6157a, total anti-GPR20 antibody, and MAAA-1181a following intravenous administration of DS-6157a [ Time Frame: Post Cycle 1 and Cycle 3 doses (each cycle is 21 days) ]
  5. Pharmacokinetic Analysis: Lowest concentration reached after a single dose (Ctrough) for DS-6157a, total anti-GPR20 antibody, and MAAA-1181a following intravenous administration of DS-6157a [ Time Frame: Post Cycle 1 and Cycle 3 doses (each cycle is 21 days) ]
  6. Pharmacokinetic Analysis: Terminal elimination half-life (t1/2) for DS-6157a, total anti-GPR20 antibody, and MAAA-1181a following intravenous administration of DS-6157a [ Time Frame: Post Cycle 1 and Cycle 3 doses (each cycle is 21 days) ]
  7. Objective response rate (ORR) following intravenous administration of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST) (Dose escalation) [ Time Frame: Baseline up to 5 years post-treatment ]
  8. Duration of response (DoR) following intravenous administration of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST) (Dose escalation) [ Time Frame: Baseline up to 5 years post-treatment ]
  9. Disease control rate (DCR) following intravenous administration of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST) (Dose escalation) [ Time Frame: Baseline up to 5 years post-treatment ]
  10. Progression-free survival (PFS) following intravenous administration of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST) (Dose escalation) [ Time Frame: Baseline up to 5 years post-treatment ]
  11. Number of participants with anti-drug antibodies against DS-6157a following intravenous administration of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST) [ Time Frame: Baseline up to 5 years post-treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent
  • At least 20 years old in Japan or 18 years old in other countries at the time of signature of the informed consent form (ICF), following local regulatory requirements
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Has histopathologically documented unresectable and/or metastatic GIST meeting the criteria below:
  • Dose Escalation (Part 1): Participants should meet one of the following criteria:

    1. (For US sites only) Participants with GIST who have progressed on or are intolerant to imatinib (IM) and at least one post-IM treatment or who are not candidates for post-IM standard of care treatment
    2. (For Japan sites only) Participants with GIST who have received all the existing standard of care treatments or who are not candidates for one or more available post-IM standard of care treatments
    3. Participants with GIST who are not candidates for IM or curative intent surgical treatment (i.e., subjects without activating KIT or platelet-derived growth factor receptor alpha (PDGFRa) mutations, with PDGFRa D842V mutations, or are KIT negative by local results)
  • Dose Expansion (Part 2) Cohort 1: Participants with GIST who have progressed on or are intolerant to IM and at least one post-IM treatment
  • Dose Expansion (Part 2) Cohort 2: Participants with GIST who have progressed on IM and had not received a post-IM treatment (2nd line)
  • Consents to provide fresh tumor biopsy tissue samples both before and on DS-6157a treatment for the measurement of GPR20 levels by immunohistochemistry and other biomarkers
  • Has a left ventricular ejection fraction (LVEF) ≥50% by either echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) within 28 days before study treatment
  • Has at least 1 measurable lesion based on RECIST Version 1.1 as assessed by the Investigator
  • Has adequate organ function within 7 days before the start of study treatment, defined as:

    1. Platelet count ≥100,000/mm^3
    2. Hemoglobin ≥8.5 g/dL
    3. Absolute neutrophil count ≥1,500/mm^3
    4. Creatinine clearance ≥50 mL/min
    5. Aspartate aminotransferase ≤3 × upper limit of normal (ULN) (if liver metastases are present, ≤5 × ULN)
    6. Alanine aminotransferase ≤3 × ULN (if liver metastases are present, ≤5 × ULN)
    7. Total bilirubin ≤1.5 × ULN or ≤3.0 × ULN for participants with documented history of Gilbert's Syndrome
  • Has an adequate treatment washout period prior to start of study treatment, defined as:

    1. Major surgery: ≥4 weeks (or 2 weeks for minor surgeries)
    2. Radiation therapy: ≥3 weeks (or 2 weeks for palliative radiation excluding pelvic radiation)
    3. Systemic anti-cancer therapy (except for anti-androgen for prostate cancer and bisphosphonate, denosumab, or medroxyprogesterone acetate for bone metastases):

      • Cytotoxic chemotherapy: ≥3 weeks or 5 times the terminal elimination half-life (t½) of the chemotherapeutic agent, whichever is shorter
      • Antibody and antibody-conjugates therapy: ≥3 weeks or 5 times the t½, whichever is longer
      • Prior tyrosine kinase inhibitors (TKIs): washout period from 2 to 21 days depending on the TKI
      • Immunotherapy: ≥4 weeks.
  • Male participants with female partners of childbearing potential and female participants of child-bearing potential must agree to use a highly effective form of contraception, or avoid intercourse during and upon completion of the study and for at least 4 months (for males) and for at least 7 months (for females) after the last dose of study drug.

Exclusion Criteria:

  • History of an allogeneic bone marrow or solid organ transplant within 3 months before the start of study treatment
  • Concomitant treatment with any medication that is classified as having a known risk of Torsades de pointes should be avoided from the start of study treatment through the end of Cycle 3
  • Prophylactic administration of granulocyte colony-stimulating factor (G-CSF), filgrastim, pegfilgrastim, erythropoietin, or the transfusion of blood, red blood cells, or platelets within 14 days before the start of treatment and during Cycle 1. Chronic therapy with erythropoietin at stable dose that started at least 14 days before the first dose of DS-6157a may continue.
  • Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, Grade ≤1. Participants with chronic Grade 2 toxicities may be eligible.
  • Has spinal cord compression or clinically active central nervous system (CNS) metastases (including brain metastases), defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms
  • Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product
  • Has a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety, efficacy, or any other assessments of the investigational regimen
  • Has a documented history of myocardial infarction or unstable angina within 6 months before study treatment
  • Has a medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or a serious cardiac arrhythmia requiring treatment
  • Has a corrected QT by Fridericia's formula (QTcF), of >470 ms based on the average of triplicate 12-lead electrocardiogram (ECG) per local read
  • Has a documented history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  • Has clinically significant pulmonary compromise or requirement for supplemental oxygen
  • Has clinically significant corneal disease
  • Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
  • Has active human immunodeficiency virus (HIV) infection as determined by plasma HIV RNA viral load.
  • Has evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, as manifest by the detectable viral load (HBV-DNA or HCV-RNA, respectively)
  • Is a lactating mother (women who are willing to temporarily interrupt breastfeeding will also be excluded), or pregnant as confirmed by pregnancy tests performed within 7 days before study treatment
  • Women who plan to become pregnant while in the study and for at least 7 months after the last administration of study treatment
  • Men who plan to father a child while in the study and for at least 4 months after the last administration of study treatment
  • Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, uncontrolled diabetes mellitus, active bleeding diatheses, substance abuse, or other medical condition that would increase the risk of toxicity or interfere with participation of the participant or evaluation of the clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04276415


Contacts
Layout table for location contacts
Contact: Daiichi Sankyo Contact for Clinical Trial Information 908-992-6400 CTRinfo@dsi.com
Contact: (for Asia sites) Daiichi Sankyo Contact for Clinical Trial Information +81-3-6225-1111(M-F 9-5 JST) dsclinicaltrial@daiichisankyo.co.jp

Locations
Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institue Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Site Coordinator         
Japan
National Cancer Center Hospital East Recruiting
Tokyo, Japan, 277-8577
Contact: See Central Contact         
Sponsors and Collaborators
Daiichi Sankyo, Inc.
Investigators
Layout table for investigator information
Study Director: Global Clinical Leader Daiichi Sankyo, Inc.
Layout table for additonal information
Responsible Party: Daiichi Sankyo, Inc.
ClinicalTrials.gov Identifier: NCT04276415    
Other Study ID Numbers: DS6157-A-U101
First Posted: February 19, 2020    Key Record Dates
Last Update Posted: May 11, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
URL: https://vivli.org/ourmember/daiichi-sankyo/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Daiichi Sankyo, Inc.:
Gastrointestinal stromal tumors
DS-6157a
Anti-drug antibody conjugate
G-protein coupled receptor 20 (GPR20)
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Stromal Tumors
Neoplasms
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases